Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

226 to 250 of 321 results

UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine

11-05-2012

Confirming previous negative guidance (The Pharma Letter January 12), UK drugs watchdog the National…

AllerganBotoxEuropeJevtanaNeurologicalOncologyPharmaceuticalPricingRegulationSanofi

High expectations for new US biosimilars following FDA guidance documents

10-05-2012

In light of the upcoming FDA guidance for biosimilar approval, Novation, health care supply chain expertise…

BiotechnologyGenericsNorth AmericaPricingRegulation

Impact of Japanese drug price reductions, by P Reed Maurer

10-05-2012

Outside observers have long predicted the mandated price reductions of drugs will kill the Japanese pharmaceutical…

Asia-PacificPharmaceuticalPricingRegulation

NICE recommends Roche's Tarceva for NSCLC

10-05-2012

Having received further previously requested data from Swiss drug major Roche (ROG: SIX), the UK drugs…

EuropePharmaceuticalPricingRegulationRocheTarceva

New Zealand considers listing of NovoMix 30 and NovoSeven RT and amendment for Glucagen Hypokit

02-05-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to fund…

Asia-PacificDiabetesGlucaGenNovo NordiskNovoMixNovoSevenPharmaceuticalPricingRegulation

Ukraine to introduce reference pricing and plans for prescription system

01-05-2012

The Ukraine Ministry of Health and domestic producers of pharmaceuticals have signed a memorandum of…

EuropeGenericsHealthcarePharmaceuticalPricingRegulation

Biopharmaceuticals "no longer a growth market" in Germany

30-04-2012

After years of consistent growth, the German biopharmaceuticals market came to a juddering halt last…

BiotechnologyEuropeMarkets & MarketingPharmaceuticalPoliticsPricingRegulation

Bayer's Xarelto reimbursement backed in Canada; EMA concludes Yvidually arbitration

24-04-2012

The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR),…

BayerCardio-vascularEuropeNorth AmericaPharmaceuticalPricingRegulationReproductiveXareltoYvidually

NICE turns down Roche breast cancer drug Avastin, citing too many uncertainties

18-04-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE), said this morning…

AvastinEuropeOncologyPharmaceuticalPricingRegulationRoche

No proof of added benefit of Sativex, says German IQWiG

17-04-2012

In an early benefit assessment under to the German Act on the Reform of the Market for Medicinal Products…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingRegulationSativex

Legislative changes to hamper near-term innovative drugs market in Central Europe

16-04-2012

Due to legislative changes implemented during 2011 in most of the Central European (CE) countries, the…

EuropeGenericsMarkets & MarketingPharmaceuticalPricingRegulation

SHA to fund Roche breast cancer drug Avastin in London

12-04-2012

Women with aggressive metastatic breast cancer in the UK capital London now have access to a drug which…

AvastinOncologyPharmaceuticalPricingRegulationRoche

Germany's IQWiG finds some benefit for Pfizer orphan drug Vyndaqel

11-04-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed Vyndaqel (tafamidis),…

EuropePfizerPharmaceuticalPricingRare diseasesRegulationVyndaqel

French Transparency Commission issues favorable opinion on Esbriet

10-04-2012

There was good news last week for USA-based InterMune (Nasdaq: ITMN) when the Transparency Commission…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Canadian patients wait two and a half years for new drug access

09-04-2012

As a result of government bureaucracies to approve new prescription drugs for public use, Canadians are…

North AmericaPharmaceuticalPoliticsPricingRegulation

Eisai breast cancer drug still viewed as not cost effective by NICE

03-04-2012

In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

German IQWiG finds mixed added benefits for Eliquis

02-04-2012

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

NICE recommendations on Bayer's Xarelto and Amgen Xgeva's for UK NHS use

30-03-2012

Following the receipt of further evidence from Bayer HealthCare, a unit of German drugmaker Bayer (BAY:…

AmgenBayerCardio-vascularEuropeOncologyPharmaceuticalPricingRegulationXareltoXgeva

"NICE" news for Novartis CML drugs, but not for Bristol-Myers

22-03-2012

In final draft guidance issued this morning, UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

226 to 250 of 321 results

Back to top